Antimicrobial efficacy of a hemilabile Pt(II)-NHC compound against drug-resistant S. aureus and Enterococcus .
Mandeep KaurRitesh P ThakareArindom BhattacheryaPrem Anand MuruganGrace KaulManjulika ShuklaAlok Kr SinghSaravanan MatheshwaranSidharth ChopraJitendra K BeraPublished in: Dalton transactions (Cambridge, England : 2003) (2023)
Three platinum(II)-N-heterocyclic carbene (NHC) compounds [Pt(L 1 )Cl](PF 6 ) (1), [Pt(L 2 )(COD)](PF 6 ) 2 (2) and [Pt(L 2 )Cl 2 ] (3) were synthesized bearing pyridyl-functionalized butenyl-tethered (L 1 H) and n -butyl tethered (L 2 H) NHC ligands, and their antibacterial activity against clinically relevant human pathogens was evaluated. Complex 1 was designed to have one of its metal coordination sites masked with a hemilabile butenyl group. The antibacterial activity spectrum against the ESKAPE panel of pathogens shows superior activity of 1 compared to 2 and 3 against the Gram-positive S. aureus pathogen. Complex 1 showed equipotent activity against clinical drug-resistant S. aureus and Enterococcus isolates. Furthermore, 1 demonstrated concentration-dependent bactericidal activity with a long post-antibiotic effect, eradicated preformed S. aureus biofilm and synergized with gentamicin and minocycline for combinatorial antimicrobial therapy. Under in vivo conditions, 1 displayed potent activity in reducing bacterial load in a murine thigh infection model, similar to vancomycin, albeit at 2.5× less dosage. An array of experiments reveals key characteristics for the hemilabile complex 1 as a potential anti-staphylococcal drug.
Keyphrases
- drug resistant
- multidrug resistant
- staphylococcus aureus
- gram negative
- acinetobacter baumannii
- endothelial cells
- biofilm formation
- candida albicans
- risk assessment
- pseudomonas aeruginosa
- escherichia coli
- stem cells
- methicillin resistant staphylococcus aureus
- high resolution
- climate change
- cystic fibrosis
- replacement therapy
- adverse drug